Effects of intramuscular vatinoxan (MK-467), co-administered with medetomidine and butorphanol, on cardiopulmonary and anaesthetic effects of intravenous ketamine in dogs

Show full item record



Permalink

http://hdl.handle.net/10138/320199

Citation

Turunen , H , Raekallio , M , Honkavaara , J , Jaakkola , J , Scheinin , M , Männikkö , S , Hautajärvi , H , Bennett , R & Vainio , O 2020 , ' Effects of intramuscular vatinoxan (MK-467), co-administered with medetomidine and butorphanol, on cardiopulmonary and anaesthetic effects of intravenous ketamine in dogs ' , Veterinary Anaesthesia and Analgesia , vol. 47 , no. 5 , pp. 604-613 . https://doi.org/10.1016/j.vaa.2020.05.008

Title: Effects of intramuscular vatinoxan (MK-467), co-administered with medetomidine and butorphanol, on cardiopulmonary and anaesthetic effects of intravenous ketamine in dogs
Author: Turunen, Heta; Raekallio, Marja; Honkavaara, Juhana; Jaakkola, Johanna; Scheinin, Mika; Männikkö, Sofia; Hautajärvi, Heidi; Bennett, Rachel; Vainio, Outi
Contributor organization: Equine and Small Animal Medicine
Helsinki One Health (HOH)
DAPHNE - Developing Assessment Practices in Higher Education
Teachers' Academy
Marja Raekallio / Principal Investigator
Veterinary Teaching Hospital
Departments of Faculty of Veterinary Medicine
Outi Vainio / Principal Investigator
Research Centre for Animal Welfare
Date: 2020-09
Language: eng
Number of pages: 10
Belongs to series: Veterinary Anaesthesia and Analgesia
ISSN: 1467-2987
DOI: https://doi.org/10.1016/j.vaa.2020.05.008
URI: http://hdl.handle.net/10138/320199
Abstract: Objective To investigate the impact of intramuscular (IM) co-administration of the peripheral alpha(2)-adrenoceptor agonist vatinoxan (MK-467) with medetomidine and butorphanol prior to intravenous (IV) ketamine on the cardiopulmonary and anaesthetic effects in dogs, followed by atipamezole reversal. Study design Randomized, masked crossover study. Animals A total of eight purpose-bred Beagle dogs aged 3 years. Methods Each dog was instrumented and administered two treatments 2 weeks apart: medetomidine (20 mu g kg(-1)) and butorphanol (100 mu g kg(-1)) premedication with vatinoxan (500 mu g kg(-1); treatment MVB) or without vatinoxan (treatment MB) IM 20 minutes before IV ketamine (4 mg kg(-1)). Atipamezole (100 mu g kg(-1)) was administered IM 60 minutes after ketamine. Heart rate (HR), mean arterial (MAP) and central venous (CVP) pressures and cardiac output (CO) were measured; cardiac (CI) and systemic vascular resistance (SVRI) indices were calculated before and 10 minutes after MVB or MB, and 10, 25, 40, 55, 70 and 100 minutes after ketamine. Data were analysed with repeated measures analysis of covariance models. A p-value Results At most time points, HR and CI were significantly higher, and SVRI and CVP significantly lower with MVB than with MB. With both treatments, SVRI and MAP decreased after ketamine, whereas HR and CI increased. MAP was significantly lower with MVB than with MB; mild hypotension (57-59 mmHg) was recorded in two dogs with MVB prior to atipamezole administration. Sedation, induction, intubation and recovery scores were not different between treatments, but intolerance to the endotracheal tube was observed earlier with MVB. Conclusions and clinical relevance Haemodynamic performance was improved by vatinoxan co-administration with medetomidine-butorphanol, before and after ketamine administration. However, vatinoxan was associated with mild hypotension after ketamine with the dose used in this study. Vatinoxan shortened the duration of anaesthesia.
Subject: anaesthesia
butorphanol
cardiopulmonary
ketamine
medetomidine
vatinoxan
PERIPHERAL ALPHA-2-ADRENOCEPTOR ANTAGONIST
ALPHA(2)-ADRENERGIC RECEPTOR ANTAGONIST
ADRENOCEPTOR ANTAGONIST
CLINICAL-EFFICACY
DEXMEDETOMIDINE
COMBINATION
SEDATION
PROPOFOL
SAFETY
413 Veterinary science
Peer reviewed: Yes
Rights: cc_by_nc_nd
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S1467298720301057_main.pdf 662.1Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record